DDInter128 DDInter927
Astemizole is a long-acting, non-sedating second generation antihistamine used in the treatment of allergy symptoms. It was withdrawn from market by the manufacturer in 1999 due to the potential to cause arrhythmias at high doses, especially when when taken with CYP inhibitors or grapefruit juice.
Inotuzumab ozogamicin is an antibody-drug conjugate using linker and cytotoxic drug technology similar to that developed for the ground-breaking treatment Mylotarg (), which was approved by the US FDA in 2000 for the treatment of acute myeloid leukaemia. Inotuzumab ozogamicin consists of a recombinant humanised IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin dimethylhydrazide, which is a potent DNA-binding cytotoxic agent . Developed by Pfizer and UCB, inotuzumab ozogamicin was granted approval by EU in June 2017 followed by FDA on August 17th, 2017 for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). ALL is a rapidly progressing cancer of the bone marrow that is associated with high mortality rates and low therapeutic response from standard chemotherapies in relasping conditions. In a randomized trial, inotuzumab ozogamicin displayed higher percentages of patients undergoing longer periods of complete remission with no evidence of disease in comparison to patients receiving alternative chemotherapy .
Astemizole {u} (Compound) resembles {v} (Compound) Fentanyl
Astemizole {u} (Compound) resembles {v} (Compound) Flunarizine
Astemizole {u} may lead to a major life threatening interaction when taken with {v} Pimozide
Astemizole {u} (Compound) binds {v} (Gene) CYP3A7-CYP3A51P
Astemizole {u} (Compound) upregulates {v} (Gene) LIPA
Astemizole {u} (Compound) downregulates {v} (Gene) RPS4Y1
Astemizole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Modafinil
Astemizole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Thalidomide
Astemizole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sorafenib
Astemizole {u} may lead to a major life threatening interaction when taken with {v} Methadone
Astemizole (Compound) resembles Fentanyl (Compound)
Astemizole (Compound) resembles Flunarizine (Compound)
Astemizole may lead to a major life threatening interaction when taken with Pimozide
Astemizole (Compound) binds CYP3A7-CYP3A51P (Gene)
Astemizole (Compound) upregulates LIPA (Gene)
Astemizole (Compound) downregulates RPS4Y1 (Gene)
Astemizole may cause a minor interaction that can limit clinical effects when taken with Modafinil
Astemizole may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide
Astemizole may cause a moderate interaction that could exacerbate diseases when taken with Sorafenib
Astemizole may lead to a major life threatening interaction when taken with Methadone